Read the IP Management Blog - Practical solutions to help you manage your IP portfolio

Dr. Bernard J. Greenspan

Dr. Bernard Greenspan has over 30 years of leadership experience in intellectual property strategy and portfolio management, drug delivery, and device research and development. His principal strengths include intellectual property strategies and law, team building, staff mentoring, and knowledge of GLP, GMP, and FDA regulations. Bernie is licensed to practice at the U.S. Patent and Trademark Office as a Patent Agent (Registration No. 50,598).

Prior to starting Greenspan IP Management, Bernie was the Senior Director of Intellectual Property at Verus Pharmaceuticals in San Diego. He was responsible for establishing IP strategies for drug product and device development teams, managing outside counsel activities, and IP support of due diligence. Therapeutic areas included asthma, anaphylaxis, and gastroesophageal diseases. Commercial products included Twinject®.

For seven years, Bernie was the Senior Director of Intellectual Property at Prometheus Laboratories, a diagnostics and therapeutics company. Prometheus was acquired by Nestlé Health Science and responsibilities extended to managing IP for both Prometheus and for Pamlab, a medical foods company in Covington, LA. During his tenure at Prometheus, Bernie was responsible for all aspects of the company's IP, as well as due diligence work on acquisitions and divestitures. Therapeutic areas included gastrosintestinal diagnostics and therapeutics, oncology diagnostics and therapeutics, and brain health therapeutics.

Bernie was also the Director of IP Strategy Management for Pfizer La Jolla Laboratories. At Pfizer, he was led IP lifecycle planning for early and late stage candidates and commercial products. Therapeutic areas included ophthalmology, oncology, virology, diabetes/obesity, and respiratory. Commercial products included Sutent®, Xalatan®, Macugen®, Viracept®, and Spiriva®. Bernie also developed educational modules for attorney groups, candidate and product teams, and new employee orientations.

Bernie in on the board of the San Diego Intellectual Property Law Assocaition (SDIPLA), has served as co-chair of the Intellectual Property Committee for BIOCOM, a regional life science organization, and he served on board of the San Diego Economic Development Foundation and the Economic Development Corporation Workforce Education Committee.

Bernie's research and development career has included positions as Director of Aerosol Technology at Dura and Elan Pharmaceuticals where he led basic and applied research in support of new technology, inhalation drug delivery products, and inhaler design leading to the creation of patented new inhaler systems; and Staff Scientist/Technical Group Leader at Battelle Pacific Northwest National Laboratory where he led scientists and engineers conducting inhalation toxicology studies.

Dr. Greenspan earned his Masters and Ph.D. in Biophysics from the University of Rochester School of Medicine and Dentistry in 1981. His research focused on aerosol physics and the deposition and clearance of cadmium aerosols and their effects on macrophages and the lungs. He also holds a Bachelor of Arts with Honors in Physics from Clark University.

Bernie also teaches the Intellectual Property Law course at the University of California San Diego Extension Program, as well as guest lecturing in various courses in the Rady School of Management.

Bernie is a co-inventor on 10 US patents and is an author on over 20 peer-reviewed publications.

 

 

 

 

Return to top